Phase II study with Fp Spiromax vs placebo in patients with Asthma

• Research type

  Research Study

• Full title

  A 12-Week Dose-ranging Study to Evaluate the Efficacy and Safety of Fp Spiromax® (Fluticasone Propionate Inhalation Powder) Administered Twice Daily compared with Placebo in Adolescent and Adult Subjects with Severe Persistent Asthma Uncontrolled on High dose Inhaled Corticosteroid Therapy

• IRAS ID

  115142

• Contact name

  Tariq Sethi

• Contact email

  tariq.sethi@kcl.ac.uk

• Sponsor organisation

  Teva Branded Pharmaceutical Products R+D, Inc.

• Eudract number

  2010-023601-35

• Clinicaltrials.gov Identifier

  NCT01576718

• REC name

  South Central - Hampshire A Research Ethics Committee

• REC reference

  12/SC/0624

• Date of REC Opinion

  15 Apr 2013

• REC opinion

  Further Information Favourable Opinion